(CTRE) CareTrust REIT - Ratings and Ratios
Senior Living Properties, Healthcare REITs, Net Lease
CTRE EPS (Earnings per Share)
CTRE Revenue
Description: CTRE CareTrust REIT
CareTrust REIT Inc. (NYSE:CTRE) is a self-administered real estate investment trust that specializes in owning, acquiring, developing, and leasing seniors housing and healthcare-related properties. The company generates revenue primarily through leasing properties to a diverse range of operators and healthcare services providers.
As of March 31, 2025, CareTrust REIT has a portfolio of 249 net-leased healthcare properties across 32 states, with 27,229 operating beds/units. Additionally, the company has 21 other real estate-related investments tied to 113 healthcare properties across 17 states, with 11,968 operating beds/units, and a financing receivable related to 46 properties in one state with 3,820 operating beds/units.
To further analyze CTREs performance, we can examine key performance indicators (KPIs) such as Funds From Operations (FFO) and Adjusted Funds From Operations (AFFO). FFO is a critical metric for REITs, as it provides a more accurate picture of a companys operating performance. A growing FFO and AFFO would indicate a healthy and sustainable business model. Additionally, the companys debt-to-equity ratio and interest coverage ratio can provide insight into its capital structure and ability to meet its financial obligations.
From a valuation perspective, we can consider metrics such as the Price-to-FFO ratio and the dividend yield. A reasonable Price-to-FFO ratio would suggest that the stock is fairly valued, while a stable and attractive dividend yield would indicate a potentially appealing investment opportunity. As a Health Care REIT, CTREs performance is also influenced by industry trends, such as the demand for seniors housing and healthcare services, and the companys ability to adapt to changing regulatory environments.
CTRE Stock Overview
| Market Cap in USD | 6,590m |
| Sub-Industry | Health Care REITs |
| IPO / Inception | 2014-05-29 |
CTRE Stock Ratings
| Growth Rating | 62.7 |
| Fundamental | 63.3% |
| Dividend Rating | 69.5 |
| Rel. Strength | 24.6 |
| Analysts | 4.22 of 5 |
| Fair Price Momentum | 36.28 USD |
| Fair Price DCF | 30.47 USD |
CTRE Dividends
| Dividend Yield 12m | 4.01% |
| Yield on Cost 5y | 8.54% |
| Annual Growth 5y | 3.01% |
| Payout Consistency | 91.1% |
| Payout Ratio | 103.3% |
CTRE Growth Ratios
| Growth Correlation 3m | 91.5% |
| Growth Correlation 12m | 20.1% |
| Growth Correlation 5y | 76.2% |
| CAGR 5y | 18.28% |
| CAGR/Max DD 5y | 0.59 |
| Sharpe Ratio 12m | 1.26 |
| Alpha | 21.84 |
| Beta | 0.076 |
| Volatility | 18.42% |
| Current Volume | 9247.3k |
| Average Volume 20d | 1656.2k |
| Stop Loss | 32.8 (-3.2%) |
| Signal | 1.38 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (219.7m TTM) > 0 and > 6% of Revenue (6% = 18.2m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 75.76% (prev 207.5%; Δ -131.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 314.6m > Net Income 219.7m (YES >=105%, WARN >=100%) |
| Net Debt (-306.1m) to EBITDA (306.5m) ratio: -1.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (192.9m) change vs 12m ago 32.76% (target <= -2.0% for YES) |
| Gross Margin 88.37% (prev 95.13%; Δ -6.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.25% (prev 7.91%; Δ 0.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.26 (EBITDA TTM 306.5m / Interest Expense TTM 33.1m) >= 6 (WARN >= 3) |
Altman Z'' -0.01
| (A) 0.05 = (Total Current Assets 406.1m - Total Current Liabilities 176.2m) / Total Assets 4.66b |
| (B) -0.11 = Retained Earnings (Balance) -528.4m / Total Assets 4.66b |
| (C) 0.07 = EBIT TTM 240.4m / Avg Total Assets 3.68b |
| (D) -0.38 = Book Value of Equity -507.4m / Total Liabilities 1.33b |
| Total Rating: -0.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.28
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 3.95% = 1.98 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.40 = 2.42 |
| 5. Debt/Ebitda 4.34 = -2.50 |
| 6. ROIC - WACC 1.27% = 1.59 |
| 7. RoE 7.60% = 0.63 |
| 8. Rev. Trend 83.15% = 4.16 |
| 9. Rev. CAGR 33.74% = 2.50 |
| 10. EPS Trend data missing |
| 11. EPS CAGR 86.43% = 2.50 |
What is the price of CTRE shares?
Over the past week, the price has changed by +3.04%, over one month by +10.39%, over three months by +19.68% and over the past year by +27.07%.
Is CareTrust REIT a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTRE is around 36.28 USD . This means that CTRE is currently overvalued and has a potential downside of 7.02%.
Is CTRE a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CTRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.9 | -0.1% |
| Analysts Target Price | 31.9 | -5.9% |
| ValueRay Target Price | 39.3 | 16% |
Last update: 2025-08-14 02:55
CTRE Fundamental Data Overview
CCE Cash And Equivalents = 306.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 27.041
P/E Forward = 12.9702
P/S = 17.6469
P/B = 1.9965
P/EG = 1.26
Beta = 0.872
Revenue TTM = 303.5m USD
EBIT TTM = 240.4m USD
EBITDA TTM = 306.5m USD
Long Term Debt = 1.16b USD (from longTermDebt, last quarter)
Short Term Debt = 176.2m USD (from totalCurrentLiabilities, last quarter)
Debt = 1.33b USD (Calculated: Short Term 176.2m + Long Term 1.16b)
Net Debt = -306.1m USD (from netDebt column, last quarter)
Enterprise Value = 7.62b USD (6.59b + Debt 1.33b - CCE 306.1m)
Interest Coverage Ratio = 7.26 (Ebit TTM 240.4m / Interest Expense TTM 33.1m)
FCF Yield = 3.95% (FCF TTM 301.1m / Enterprise Value 7.62b)
FCF Margin = 99.22% (FCF TTM 301.1m / Revenue TTM 303.5m)
Net Margin = 72.41% (Net Income TTM 219.7m / Revenue TTM 303.5m)
Gross Margin = 88.37% ((Revenue TTM 303.5m - Cost of Revenue TTM 35.3m) / Revenue TTM)
Tobins Q-Ratio = -15.01 (set to none) (Enterprise Value 7.62b / Book Value Of Equity -507.4m)
Interest Expense / Debt = 0.98% (Interest Expense 13.0m / Debt 1.33b)
Taxrate = 0.55% (from yearly Income Tax Expense: 681.0k / 124.4m)
NOPAT = 239.1m (EBIT 240.4m * (1 - 0.55%))
Current Ratio = 2.30 (Total Current Assets 406.1m / Total Current Liabilities 176.2m)
Debt / Equity = 0.40 (Debt 1.33b / last Quarter total Stockholder Equity 3.30b)
Debt / EBITDA = 4.34 (Net Debt -306.1m / EBITDA 306.5m)
Debt / FCF = 4.42 (Debt 1.33b / FCF TTM 301.1m)
Total Stockholder Equity = 2.89b (last 4 quarters mean)
RoA = 4.72% (Net Income 219.7m, Total Assets 4.66b )
RoE = 7.60% (Net Income TTM 219.7m / Total Stockholder Equity 2.89b)
RoCE = 5.94% (Ebit 240.4m / (Equity 2.89b + L.T.Debt 1.16b))
RoIC = 6.68% (NOPAT 239.1m / Invested Capital 3.58b)
WACC = 5.40% (E(6.59b)/V(7.92b) * Re(6.30%)) + (D(1.33b)/V(7.92b) * Rd(0.98%) * (1-Tc(0.01)))
Shares Correlation 5-Years: 100.0 | Cagr: 14.84%
Discount Rate = 6.30% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.50% ; FCFE base≈254.1m ; Y1≈277.0m ; Y5≈349.3m
Fair Price DCF = 30.47 (DCF Value 6.09b / Shares Outstanding 199.7m; 5y FCF grow 10.26% → 3.0% )
Revenue Correlation: 83.15 | Revenue CAGR: 33.74%
Revenue Growth Correlation: 70.63%
EPS Correlation: N/A | EPS CAGR: 86.43%
EPS Growth Correlation: 20.69%
Additional Sources for CTRE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle